Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HBB | P68871 | 1/20 | 0.35 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15182740 | 0.88 | CA12 (0.61) | CA12CA2CA3CA4CA6 | |
| SCHEMBL12890945 | 0.88 | CA12 (0.61) | CA12CA2CA3CA4CA6 | |
| SCHEMBL12156851 | 0.88 | ARG1 (0.36) | CA12CA2CA3CA4CA6 | |
| SCHEMBL13649903 | 0.88 | CHRM2 (0.36) | CA12CA2CA3CA4CA6 | |
| SCHEMBL21472709 | 0.86 | CHRM2 (0.40) | CA12CA2CA3CA4CA6 | |
| SCHEMBL12890963 | 0.86 | MAPT (0.41) | CA12CA2CA3CA4CA6 | |
| SCHEMBL13407589 | 0.84 | — | — | |
| SCHEMBL12890948 | 0.84 | TSHR (0.32) | TSHR | |
| SCHEMBL22299488 | 0.84 | PRMT1 (0.48) | — | |
| SCHEMBL20805129 | 0.84 | CHRM2 (0.44) | TSHRGGPS1FDPSAGTR1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029790-B2 | Biomimetic nanomaterials and uses thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230323027-A1 | POLYMERISATION PROCESS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-10-12 | — | — | US | disclosed |
| US-20230181743-A1 | FUNCTIONAL LIPID DERIVATIVES AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-06-15 | — | — | US | disclosed |
| US-20230097358-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20220402966-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2022-12-22 | — | — | US | disclosed |
| EP-3386473-B1 | OLIGOESTER AMMONIUM SALTS AND THEIR USE IN COSMETIC COMPOSITIONS | CLARIANT INT LTD (CH) | 2022-04-20 | — | — | EP | disclosed |
| US-20210315896-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2021-10-14 | — | — | US | disclosed |
| US-11040998-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| EP-3277286-B1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2021-04-21 | — | — | EP | disclosed |
| US-20200109164-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2020-04-09 | — | — | US | disclosed |
| US-20160289262-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2016-10-06 | — | — | US | disclosed |
| US-8143282-B2 | Heterocyclic compounds | S*BIO PTE LTD. (SG) | 2012-03-27 | — | — | US | disclosed |
| EP-1896363-B1 | EUO STRUCTURAL TYPE ZEOLITE CONTAINING THE CATION N,N- DIMETHYL-N,N-DI(3,3-DIMETHYLBUTYL)AMMONIUM, AND THE PRODUCTION METHOD THEREOF | INST FRANCAIS DU PETROLE (FR) | 2012-01-25 | — | — | EP | disclosed |
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S'BIO PTE LTD (SG) | 2010-04-22 | — | — | US | disclosed |
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S'BIO PTE LTD (SG) | 2010-04-22 | — | — | US | disclosed |
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090048300-A1 | Heterocyclic Compounds | S*BIO PTE LTD. (SG) | 2009-02-19 | — | — | US | disclosed |
| US-7456203-B2 | Muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1980532-A1 | Method for preparing a beta zeolite | IFP (FR) | 2008-10-15 | — | — | EP | disclosed |
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040998-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | GPBAR1, NR1H4, SLC10A1 | CA12 2446/4885CA2 1361/4885CA3 1259/4885 |
| US-20210315896-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | CA12 4822/4885CA2 4388/4885CA3 4618/4885 |
| US-20220402966-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | GPBAR1, NR1H4, SLC10A1 | CA12 2446/4885CA2 1361/4885CA3 1259/4885 |
| US-20090048300-A1 | Heterocyclic Compounds | HDAC1, HDAC3, HDAC11 | CA12 1998/4885CA2 1473/4885CA3 1420/4885 |
| US-20160289262-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | GPBAR1, NR1H4, SLC10A1 | CA12 2446/4885CA2 1361/4885CA3 1259/4885 |
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | PAICS, HDAC5, HDAC4 | CA12 636/4885CA2 704/4885CA3 2097/4885 |
| US-20200109164-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | GPBAR1, NR1H4, SLC10A1 | CA12 2446/4885CA2 1361/4885CA3 1259/4885 |
| US-12029790-B2 | Biomimetic nanomaterials and uses thereof | MTREX, HAVCR2, TSG101 | CA12 234/4885CA2 1634/4885CA3 3074/4885 |
| US-20230181743-A1 | FUNCTIONAL LIPID DERIVATIVES AND USES THEREOF | LIPA, LIPG, LIPC | CA12 2986/4885CA2 3988/4885CA3 4612/4885 |
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | KCNN3, KCNN2, HCN3 | CA12 3310/4885CA2 222/4885CA3 248/4885 |
| US-20230097358-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | CA12 4822/4885CA2 4388/4885CA3 4618/4885 |
| US-20090306134-A1 | Muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | CA12 2548/4885CA2 2042/4885CA3 3511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.